Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Cost-effectiveness of sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer in China

Fig 2

Tornado diagram of one-way sensitivity analyses of sacituzumab tirumotecan versus chemotherapy.

PFS, progression-free survival; PD, progressed disease; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.

Fig 2

doi: https://doi.org/10.1371/journal.pone.0343330.g002